Atai Life Sciences BV

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company, which engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

COMPASS Pathways

Cybin

Will tough times continue for psychedelic stocks? Analyst Alex Carchidi shares his views on the sector and specific stocks like Compass Pathways, Atai and Cybin.

Psychedelic Stocks: Don't Bet On Just 1 Company

The U.S. Food and Drug Administration on Friday issued its first draft guidance on psychedelic drug clinical trials, outlining considerations for companies investigating the drugs' potential to treat psychiatric and substance-use disorders and other medical conditions. Psychedelics are increasingly drawing attention from researchers, biotech companies and investors interested in their potential to help address the U.S. mental-health crisis.

FDA issues guidance on psychedelic drug clinical trials

Mind Medicine MindMed

Blake Mycoskie, founder of the canvas-footwear phenomenon TOMS Shoes, has committed to giving $100 million to support psychedelic research and access, Mycoskie told MarketWatch in an exclusive interview. The money will help fund academic institutions investigating psychedelics' potential to treat anxiety, depression, post-traumatic stress disorder and other mental-health issues, as well as nonprofits helping to connect patients in need with psychedelic treatments.

TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.

NEW YORK and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming June Investor Conferences.

atai Life Sciences to Participate in Upcoming June Investor Conferences

Rigel Pharmaceuticals

Sorrento Therapeutics Inc

When it comes to investing, penny stocks often evoke a sense of intrigue and opportunity. These low-priced securities, typically traded under $5 per share, can potentially deliver substantial gains quickly.

3 Penny Stocks to Make You the Millionaire Next Door

NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported first quarter 2023 financial results and provided corporate updates.

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference.

atai Life Sciences to Participate in Upcoming May Investor Conference

- Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

Atai's stock probably isn't going to spike by as much as Wall Street says. It has enough money for the next few years, and it could still raise even more.

After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?

NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience's Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine).

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Atai focuses on psychedelics to treat mental illnesses. The clinical-stage biopharmaceutical company said it has enough cash to last into 2026.

Why Shares of Atai Life Sciences Rose Friday

In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. Its sound financial position and deep clinical pipeline appear to have sparked a wave of bargain buying this week.

Why Atai Life Sciences Stock Stormed Higher This Week

NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported fourth quarter and full year 2022 financial results and provided clinical pipeline highlights.

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

The psychedelic drug boom may be taking off, but one company in the space is trimming its workforce. Atai Life Sciences (NASDAQ: ATAI ) just announced it has laid off roughly 30% of its staff.

Atai Layoffs 2023: What to Know About the Latest ATAI Job Cuts

NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, provided key clinical pipeline and corporate updates.

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference.

atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

Wall Street is bullish on these two beaten-down healthcare stocks.

Wall Street Thinks These 2 Penny Stocks Could Go Parabolic

Ameri Holdings

GH Research PLC

Advisorshares Psychedelics ETF

Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.

The 7 Most Promising Psychedelic Stocks to Buy in February

atai Life Sciences N.V. (ATAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted.

Down -34.59% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)

atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

atai Life Sciences N.V. (ATAI) Upgraded to Buy: Here's What You Should Know

Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?

Psychedelic Sunday: Competitive Strategies

Seelos Therapeutics

What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.

Scrutinizing Psychedelic Stocks

Atai Life Sciences' ketamine-based therapy failed to help patients with depression in a mid-stage trial.

The stock of psychedelics giant Atai is tumbling after a treatment failed to help patients in a trial

atai Life Sciences (NASDAQ:ATAI) shares tumbled more than 40% in pre-market trading on Friday after the company reported disappointing results from its subsidiary Perception Neuroscience's Phase 2a clinical trial of PCN-101 (R-ketamine), a stereoisomer of ketamine, for treatment-resistant depression. The biopharmaceutical company said in a statement that while PCN-101 demonstrated signs of efficacy across all time points out to two weeks, the trial did not meet its primary endpoint of a statistically significant change from baseline in participants' Montgomery-Åsberg Depression Rating Scale (MADRS) score at 24 hours compared to placebo.

atai Life Sciences shares plummet as r-ketamine candidate fails to meet primary endpoint in Phase 2a trial

Shares of Atai Life Sciences NV ATAI, -2.59% tumbled about 44% in premarket trading on Friday after the company said a Phase 2a clinical trial evaluating a ketamine therapy for treatment-resistant depression did not meet the primary endpoint. Atai's stock has declined 60.1% over the past year, while the S&P 500 SPX, -1.16% is down 19.0%.

News for Atai Life Sciences BV Stock (ATAI)